Literature DB >> 33434439

Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features.

Halis Kaan Akturk1, Robert Dowd2, Kaushik Shankar2, Mark Derdzinski2.   

Abstract

Background: Optional features of continuous glucose monitoring (CGM) systems empower patients and caregivers to understand and manage diabetes in new ways. We examined associations between use of optional features, demographics, and glycemic outcomes.
Methods: Retrospective cohort studies were performed with data from US-based users of the G6 CGM System (Dexcom, Inc.). For all cohorts, data included sensor glucose values (SGVs). In separate cohorts, use of alert features (for hyperglycemia, existing hypoglycemia, and impending hypoglycemia), remote data sharing feature (Share), software for retrospective pattern analysis (CLARITY), "virtual assistant" feature that announces the current SGV and trend in response to a spoken request were assessed. Descriptive statistics were used to summarize feature set utilization patterns and relate them to glycemic outcomes.
Results: Most individual features were consistently adopted by high proportions of G6 users. Threshold SGVs chosen for activating hyperglycemia and hypoglycemia alerts varied with age and were higher among the youngest and oldest patients. Use of the Share feature was more common among young patients and those with type 1 diabetes. Individuals who used more of the alert and notification features had more favorable glycemic outcomes, including time in range (TIR), than those who used fewer. More extensive engagement with CLARITY notifications was associated with higher TIR. Frequent use of the virtual assistant feature was associated with higher TIR and lower mean SGV. Conclusions: Optional features of the G6 CGM system are acceptable to and appear to benefit patients who use them. Different levels of engagement suggest that demographics and personal circumstances play a role in how patients and caregivers use CGM features to help manage diabetes.

Entities:  

Keywords:  CLARITY; Continuous glucose monitoring; Dexcom; Real-world data; Type 1 diabetes

Year:  2021        PMID: 33434439     DOI: 10.1089/dia.2020.0654

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  6 in total

1.  Personalized Digital Health Beyond the Pandemic.

Authors:  Joyce Hsu
Journal:  J Nurse Pract       Date:  2022-05-25       Impact factor: 0.826

2.  Time-Limited Eating and Continuous Glucose Monitoring in Adolescents with Obesity: A Pilot Study.

Authors:  Alaina P Vidmar; Monica Naguib; Jennifer K Raymond; Sarah Jeanne Salvy; Elizabeth Hegedus; Choo Phei Wee; Michael I Goran
Journal:  Nutrients       Date:  2021-10-21       Impact factor: 5.717

3.  Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes-Findings from a Large UK Centre.

Authors:  Kyuhan Lee; Shakthi Gunasinghe; Alyson Chapman; Lynne A Findlow; Jody Hyland; Sheetal Ohol; Andrea Urwin; Martin K Rutter; Jonathan Schofield; Hood Thabit; Lalantha Leelarathna
Journal:  Biosensors (Basel)       Date:  2021-11-15

4.  Beliefs Around Hypoglycemia and Their Impacts on Hypoglycemia Outcomes in Individuals with Type 1 Diabetes and High Risks for Hypoglycemia Despite Using Advanced Diabetes Technologies.

Authors:  Yu Kuei Lin; Caroline R Richardson; Iulia Dobrin; Melissa J DeJonckheere; Kara Mizokami-Stout; Michael D Fetters; James E Aikens; Simon J Fisher; Wen Ye; Rodica Pop-Busui
Journal:  Diabetes Care       Date:  2022-03-01       Impact factor: 19.112

5.  Non-adjunctive continuous glucose monitoring for control of hypoglycaemia (COACH): Results of a post-approval observational study.

Authors:  Stayce E Beck; Colleen Kelly; David A Price
Journal:  Diabet Med       Date:  2021-11-23       Impact factor: 4.213

6.  Real-World Evidence of Improved Glycemic Control in People with Diabetes Using a Bluetooth-Connected Blood Glucose Meter with a Mobile Diabetes Management App.

Authors:  Mike Grady; Hilary Cameron; Amey Bhatiker; Elizabeth Holt; Oliver Schnell
Journal:  Diabetes Technol Ther       Date:  2022-06-23       Impact factor: 7.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.